WEE1
A checkpoint kinase that gives cells time to fix DNA before dividing. Removing it forces damaged cancer cells into a fatal division.
Adavosertib showed activity in uterine serous carcinoma and TP53-mutant tumours but development was paused; azenosertib (ZN-c3) and Debio 0123 continue in ovarian and other cancers.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · A checkpoint kinase that gives cells time to fix DNA before dividing. Removing it forces damaged cancer cells into a fatal division.
- 1 · What it is
A checkpoint kinase that gives cells time to fix DNA before dividing. Removing it forces damaged cancer cells into a fatal division.
- 2 · What goes wrong in cancer
Inhibits CDK1 to enforce the G2/M checkpoint; TP53-mutant cells depend on it.
- 3 · How drugs use it
No product in this corpus aims at WEE1 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Biology
Inhibits CDK1 to enforce the G2/M checkpoint; TP53-mutant cells depend on it.
- TP53-mutant, CCNE1-amplified tumours
How common it is, by cancer
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Ovarian cancer | 15-20% | CCNE1 amplification (dependency context) | TP53 mutation ~95% | cBioPortal (TCGA) |
| Endometrial cancer | n/a | Uterine serous carcinoma context | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Latest papers
topQuery for this target: (TITLE:"WEE1" OR ABSTRACT:"WEE1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about WEE1, not a curated reading list.
Pages like this
not linked directly; found by shared links- TargetATR
Shares The p53 network (guardian of the genome), DNA replication stress, DNA damage response & homologous recombination, Synthetic lethality: paired dependencies and the tag ddr.
- TechnologyHRD & BRCA testing
Shares DNA damage response & homologous recombination, Synthetic lethality: paired dependencies, Double-strand break repair: HR versus end joining, Ovarian cancer.
- PairingPlatinum chemotherapy in HRD tumours
Shares DNA damage response & homologous recombination, Ovarian cancer, Triple-negative breast cancer (TNBC).
- TermHallmark: evading growth suppressors
Shares The cell-cycle engine (cyclins & CDKs), The p53 network (guardian of the genome), p53 / RB / cell-cycle checkpoint.
- PersonAlan Ashworth
Shares Synthetic lethality approaches, Ovarian cancer, Triple-negative breast cancer (TNBC).
- PathwayBase excision repair, PARP & alkylation damage
Shares DNA replication stress, DNA damage response & homologous recombination, Double-strand break repair: HR versus end joining, Ovarian cancer.
- IdeaTurn chromosomal chaos into a weakness with KIF18A inhibitors
Shares Synthetic lethality approaches, Ovarian cancer, Triple-negative breast cancer (TNBC).
- ProductTalazoparib
Shares DNA damage response & homologous recombination, Synthetic lethality: paired dependencies, Double-strand break repair: HR versus end joining, Triple-negative breast cancer (TNBC).